Collplant Biotechnologies Ltd income statement

In fiscal 2025, Collplant Biotechnologies Ltd reported revenue of $2.4m, up 360.4% on the year before, operating income of −$11.5m (a -484.3% margin) and net income of −$11.5m, or −$0.94 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Collplant Biotechnologies Ltd: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	5	2	6	16	0	11	1	2
Cost of revenue	2	2	3	2	0	2	2	1
Gross profit	3	0	3	14	−0	9	−1	2
Research and development	4	4	4	8	10	10	11	8
General and administrative	4	4	5	6	7	6	6	5
Operating income	−4	−8	−6	0	−17	−8	−17	−11
Income tax	—	—	—	—	—	60	46	—
Net income	−6	−11	−6	0	−17	−7	−17	−11
Diluted EPS	$1.43	−$2.23	−$0.84	$0.02	−$1.53	−$0.62	−$1.45	−$0.94
Diluted shares (average)	4m	5m	7m	12m	11m	11m	11m	12m
EBITDA	−4	−7	−5	1	−16	−6	−16	−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CLGN vs KRRO CLGN vs VTGN CLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Collplant Biotechnologies Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Collplant Biotechnologies Ltd.